A novel CEST-contrast nanoagent for differentiating the malignant degree in breast cancer-Reference-Cited by-全球学者库

A novel CEST-contrast nanoagent for differentiating the malignant degree in breast cancer

Published:2023 Issue:21 Volume:13 Page:14131-14138
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Chen Bixue¹^ORCID,Meng Xianfu²³,Wu Wanlu¹,Zhang Yuwen⁴,Ma Lin¹,Chen Kaidong¹,Fang Xiangming¹

Affiliation:

1. Department of Radiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China

2. Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China

3. Department of Materials Science, State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai, China

4. Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China

Abstract

A new nano-contrast agent had been designed to respond to the pH of the microenvironment of breast cancer, enabling CEST MRI imaging to identify the aggressiveness of different subtypes of breast cancer.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Jiangsu Province

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/RA/D3RA01006F

Reference47 articles.

1. Breast cancer statistics, 2011

2. Breast cancer

3. Cancer statistics for the year 2020: An overview

4. Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets

5. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011